ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Obituary: Lawrence Garfinkel, ACS Epidemiologist

January 22, 2010

UT-Houston Wins NIH Center Grant For Alternative Cancer Medicine Studies

November 3, 1995

DCT Board Ok’s $10.6 Mil. Renewal Of CTEP Contract

November 2, 1990

Early Clinical Trials Of Targeted Therapies Highlighted At AACR-NCI-EORTC Meeting

October 26, 2007

NCI Clamps Down On Site Visits, Announces New Policy To Reduce Number, Improve Quality

April 26, 1974

Dingell To Challenge NCI, NSABP Handling Of Fraud, Delays

April 8, 1994